| Description |
1 online resource (987 pages) |
| Contents |
Antiepileptic drugs; contents; contributing authors; preface; section i general principles; 1 principles of antiepileptic drug action; 2 neurophysiologic effects of antiepileptic drugs; 3 discovery and preclinical development of antiepileptic drugs; 4 new antiepileptic drug development: medical perspective; 5 clinical development of antiepileptic drugs: industry perspective; 6 the development of antiepileptic drugs: regulatory perspective; 7 antiepileptic drug monotherapy in adults: selection and use in new-onset epilepsy; 8 combination therapy and drug interactions |
|
9 laboratory monitoring of antiepileptic drugs 10 safety monitoring of antiepileptic drugs; 11 use of antiepileptic drugs in children; 12 antiepileptic drug use in women; 13 epilepsy in the elderly; 14 treatment of status epilepticus; 15 prevention of epileptogenesis; section ii benzodiazepines; 16 mechanisms of action; 17 chemistry, biotransformation, and pharmacokinetics; 18 clinical efficacy and use in epilepsy; 19 adverse effects; section iii carbamazepine; 20 mechanisms of action; 21 chemistry, biotransformation, and pharmacokinetics; 22 interactions with other drugs |
|
23 clinical efficacy and use in epilepsy24 clinical efficacy and use in other neurologic disorders; 25 clinical efficacy and use in psychiatric disorders; 26 adverse effects; section iv felbamate; 27 felbamate; section v gabapentin; 28 mechanisms of action; 29 chemistry, biotransformation, pharmacokinetics, and interactions; 30 clinical use; 31 clinical efficacy and use in other neurological disorders; 32 clinical efficacy and use in psychiatric disorders; 33 adverse effects; section vi lamotrigine; 34 mechanisms of action; 35 chemistry, biotransformation, and pharmacokinetics |
|
36 interaction with other drugs37 clinical efficacy and use in epilepsy; 38 efficacy and use in psychiatric disorders; 39 adverse effects; section vii i levetiracetam; 40 mechanisms of action; 41 chemistry, biotransformation, pharmacokinetics, and drug interactions; 42 clinical use; 43 adverse experiences; section viii oxcarbazepine; 44 mechanisms of action; 45 chemistry, biotransformation, and pharmacokinetics; 46 interactions with other drugs; 47 clinical efficacy and use in epilepsy; 48 clinical efficacy and use in psychiatric disorders; 49 adverse effects |
|
Section ix phenobarbital and other barbiturates50 mechanisms of action; 51 chemistry, biotransformation, and pharmacokinetics; 52 interactions with other drugs; 53 clinical efficacy and use in epilepsy; 54 clinical efficacy and use in nonepileptic disorders; 55 adverse effects; 56 methylphenobarbital; section x phenytoin and other hydantoins; 57 mechanisms of action; 58 chemistry and biotransformation; 59 interactions with other drugs; 60 clinical efficacy and use in epilepsy; 61 clinical efficacy and use in other neurological disorders; 62 clinical efficacy and use in psychiatric disorders |
| Summary |
The thoroughly revised, updated Fifth Edition of this classic is the most comprehensive, current, and authoritative reference on all anticonvulsants available today. This edition features detailed profiles of newer drugs--including levetiracetam, oxcarbazepine, tiagabine, topiramate, and zonisamide--and new chapters on use of antiepileptic drugs in children and during pregnancy. Drugs are covered in alphabetical order and in an easy-to-follow format: mechanisms of action; chemistry, biotransformation, and pharmacokinetics; interactions; clinical efficacy and use; and adverse effects. Coverage |
| Notes |
63 adverse effects |
|
Print version record |
| Subject |
Epilepsy -- Chemotherapy
|
|
Anticonvulsants.
|
|
Anticonvulsants
|
|
Anticonvulsants
|
|
Epilepsy -- Chemotherapy
|
| Form |
Electronic book
|
| Author |
Mattson, Richard H
|
|
Meldrum, Brian S
|
| ISBN |
9781469877266 |
|
1469877260 |
|
